Oxford AstraZeneca vaccine 90% more effective in small doses


The vaccine being developed with Oxford University was 90% effective when a half-dose was given before a full-dose booster, the partners said on Monday.  Most of the people in the trial received a placebo or the regimen of two full doses, which was 62% effective.  However, that regime was administered to participants in a group whose age was capped at 55, Warp Speed’s Moncef Slaoui said. Researchers have been wondering why a smaller dose of the vaccine might have appeared to be more effective than a larger one.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More